Who can use Mektovi(Binimetinib)?

Binimetinib is an oral kinase inhibitor that specifically inhibits the activity of intracellular MEK1 and MEK2 proteins, thereby blocking the abnormal activation of the RAS/RAF/MEK/ERK signaling pathway. This signaling pathway plays a crucial role in the proliferation and survival of various tumor cells.

Who can use Mektovi(Binimetinib)?

By inhibiting this pathway, binimetinib can significantly suppress the growth and spread of tumor cells, thus exerting an antitumor effect. Clinical studies have shown that the combination of binimetinib and encorafenib has demonstrated significant therapeutic effects in patients with melanoma and non-small cell lung cancer harboring specific BRAF gene mutations. It can prolong progression-free survival (PFS) and overall survival (OS), and improve the objective response rate (ORR).